Targeted Therapies in the Treatment of Colorectal CancerO'DWYER, Peter J.Seminars in oncology. 2003, Vol 30, Num 3, issn 0093-7754, 94 p., SUP6Serial Issue

Current status of oxaliplatin in colorectal cancerO'DWYER, Peter J; JOHNSON, Steven W.Seminars in oncology. 2003, Vol 30, Num 3, pp 78-87, issn 0093-7754, 10 p., SUP6Article

Cyclooxygenase-2 inhibitors in colorectal cancerSTOEHLMACHER, Jan; LENZ, Heinz-Josef.Seminars in oncology. 2003, Vol 30, Num 3, pp 10-16, issn 0093-7754, 7 p., SUP6Article

Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemopreventionYAO, Kang-Shen; O'DWYER, Peter J.Biochemical pharmacology. 2003, Vol 66, Num 1, pp 15-23, issn 0006-2952, 9 p.Article

17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell linesVASILEVSKAYA, Irina A; O'DWYER, Peter J.Biochemical pharmacology. 2005, Vol 70, Num 4, pp 580-589, issn 0006-2952, 10 p.Article

Development of ZD 1839 in colorectal cancerDOUGLASS, Edwin C.Seminars in oncology. 2003, Vol 30, Num 3, pp 17-22, issn 0093-7754, 6 p., SUP6Article

Practical considerations in the use of oral fluoropyrimidinesHOFF, Paulo Marcelo G.Seminars in oncology. 2003, Vol 30, Num 3, pp 88-92, issn 0093-7754, 5 p., SUP6Article

Monoclonal antibodies in the treatment of colorectal cancerVERONESE, Maria Luisa; O'DWYER, Peter J.European journal of cancer (1990). 2004, Vol 40, Num 9, pp 1292-1301, issn 0959-8049, 10 p.Article

Development of the epidermal growth factor receptor inhibitor OSI-774GRÜNWALD, Viktor; HIDALGO, Manuel.Seminars in oncology. 2003, Vol 30, Num 3, pp 23-31, issn 0093-7754, 9 p., SUP6Article

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancerFERNANDO, Nishan H; HURWITZ, Herbert I.Seminars in oncology. 2003, Vol 30, Num 3, pp 39-50, issn 0093-7754, 12 p., SUP6Article

Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell linesRAKITINA, Tatiana V; VASILEUSKAYA, Irina A; O'DWYER, Peter J et al.Biochemical pharmacology. 2007, Vol 73, Num 11, pp 1715-1726, issn 0006-2952, 12 p.Article

Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signalingRAKITINA, Tatiana V; VASILEVSKAYA, Irina A; O'DWYER, Peter J et al.Cancer research (Baltimore). 2003, Vol 63, Num 24, pp 8600-8605, issn 0008-5472, 6 p.Article

Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancerITAKURA, Haruka; VAUGHN, David; HALLER, Daniel G et al.The Journal of urology. 2003, Vol 169, Num 2, issn 0022-5347, p. 613Article

Optimal use of the combination of irinotecan and 5-fluorouracilBENSON, Al B; GOLDBERG, Richard M.Seminars in oncology. 2003, Vol 30, Num 3, pp 68-77, issn 0093-7754, 10 p., SUP6Article

High rate of consent to bank biologic samples for future research: The Eastern Cooperative Oncology Group ExperienceMALONE, Thomas; CATALANO, Paul J; O'DWYER, Peter J et al.Journal of the National Cancer Institute. 2002, Vol 94, Num 10, pp 769-771, issn 0027-8874Article

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with BevacizumabBATES, David O; CATALANO, Paul J; SYMONDS, Kirsty E et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6384-6391, issn 1078-0432, 8 p.Article

Phase 2 Trial of Bevacizumab, Capecitabine, and Oxaliplatin in Treatment of Advanced Hepatocellular CarcinomaWEIJING SUN; SOHAL, Davendra; SHAKED, Abraham et al.Cancer. 2011, Vol 117, Num 14, pp 3187-3192, issn 0008-543X, 6 p.Article

Inhibition of Mutated, Activated BRAF in Metastatic MelanomaFLAHERTY, Keith T; PUZANOV, Igor; CHAPMAN, Paul B et al.The New England journal of medicine. 2010, Vol 363, Num 9, pp 809-819, issn 0028-4793, 11 p.Article

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesAMARAVADI, Ravi K; SCHUCHTER, Lynn M; ATKINS, Michael B et al.Clinical cancer research (Print). 2009, Vol 15, Num 24, pp 7711-7718, issn 1078-0432, 8 p.Article

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyVONDERHEIDE, Robert H; FLAHERTY, Keith T; GREEN, Stephanie et al.Journal of clinical oncology. 2007, Vol 25, Num 7, pp 876-883, issn 0732-183X, 8 p.Article

Mechanisms of hypertension associated with BAY 43-9006VERONESE, Maria Luisa; MOSENKIS, Ari; FLAHERTY, Keith T et al.Journal of clinical oncology. 2006, Vol 24, Num 9, pp 1363-1369, issn 0732-183X, 7 p.Article

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabineFLAHERTY, Keith T; STEVENSON, James P; REDLINGER, Maryann et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 5, pp 404-408, issn 0344-5704, 5 p.Article

Follow-up of stage B and C colorectal cancer in the United States and FranceO'DWYER, Peter J; STEVENSON, James P; HALTER, Daniel G et al.Seminars in oncology. 2001, Vol 28, Num 1, pp 45-49, issn 0093-7754, SUP1Conference Paper

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction studyFLAHERTY, Keith T; LATHIA, Chetan; FRYE, Reginald F et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1111-1118, issn 0344-5704, 8 p.Article

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsTRAYNOR, Anne M; HEWITT, Maureen; O'DWYER, Peter J et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 2, pp 305-314, issn 0344-5704, 10 p.Article